Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

201 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Art therapy as a comprehensive complementary treatment for Parkinson's disease.
Ettinger T, Berberian M, Acosta I, Cucca A, Feigin A, Genovese D, Pollen T, Rieders J, Kilachand R, Gomez C, Kaimal G, Biagioni M, Di Rocco A, Ghilardi FM, Rizzo JR. Ettinger T, et al. Among authors: feigin a. Front Hum Neurosci. 2023 May 12;17:1110531. doi: 10.3389/fnhum.2023.1110531. eCollection 2023. Front Hum Neurosci. 2023. PMID: 37250693 Free PMC article.
What Huntington's Disease Patients Say About Their Illness: An Online Direct-to-Participant Pilot Study.
Anderson KE, Arbatti L, Hosamath A, Feigin A, Goldstein J, Kayson E, Kinsler BL, Falanga L, Denise L, Carlozzi NE, Frank S, Jackson K, Kostyk S, Purks JL, Serbin KP, Kinel S, Beck CA, Shoulson I. Anderson KE, et al. Among authors: feigin a. J Huntingtons Dis. 2024 Apr 30. doi: 10.3233/JHD-231520. Online ahead of print. J Huntingtons Dis. 2024. PMID: 38701155
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
Reilmann R, Anderson KE, Feigin A, Tabrizi SJ, Leavitt BR, Stout JC, Piccini P, Schubert R, Loupe P, Wickenberg A, Borowsky B, Rynkowski G, Volkinshtein R, Li T, Savola JM, Hayden M, Gordon MF; LEGATO-HD Study Group. Reilmann R, et al. Among authors: feigin a. Lancet Neurol. 2024 Mar;23(3):243-255. doi: 10.1016/S1474-4422(23)00454-4. Epub 2024 Jan 24. Lancet Neurol. 2024. PMID: 38280392 Clinical Trial.
Using a smartwatch and smartphone to assess early Parkinson's disease in the WATCH-PD study.
Adams JL, Kangarloo T, Tracey B, O'Donnell P, Volfson D, Latzman RD, Zach N, Alexander R, Bergethon P, Cosman J, Anderson D, Best A, Severson J, Kostrzebski MA, Auinger P, Wilmot P, Pohlson Y, Waddell E, Jensen-Roberts S, Gong Y, Kilambi KP, Herrero TR, Ray Dorsey E; Parkinson Study Group Watch-PD Study Investigators and Collaborators. Adams JL, et al. NPJ Parkinsons Dis. 2023 Apr 17;9(1):64. doi: 10.1038/s41531-023-00497-x. NPJ Parkinsons Dis. 2023. PMID: 37069193 Free PMC article.
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study.
Frank S, Testa C, Edmondson MC, Goldstein J, Kayson E, Leavitt BR, Oakes D, O'Neill C, Vaughan C, Whaley J, Gross N, Gordon MF, Savola JM; Huntington Study Group/ARC-HD Investigators and Coordinators. Frank S, et al. CNS Drugs. 2022 Nov;36(11):1207-1216. doi: 10.1007/s40263-022-00956-8. Epub 2022 Oct 15. CNS Drugs. 2022. PMID: 36242718 Free PMC article. Clinical Trial.
Publisher Correction: Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trial.
Feigin A, Evans EE, Fisher TL, Leonard JE, Smith ES, Reader A, Mishra V, Manber R, Walters KA, Kowarski L, Oakes D, Siemers E, Kieburtz KD, Zauderer M; Huntington Study Group SIGNAL investigators. Feigin A, et al. Nat Med. 2024 Feb;30(2):606. doi: 10.1038/s41591-022-02070-0. Nat Med. 2024. PMID: 36195687 Free PMC article. No abstract available.
201 results